The Care Notebook

When thymalfasin comes up

Open the notebook

Thymosin alpha-1 treatment.

The mix-up

Myth: If a treatment is offered online, it has passed an official review.

The answer

The FDA reviews medicines. As of September 28, 2026, it has granted no US approval to a thymosin alpha-1 medicine.

What it actually is

Thymosin alpha-1 is a peptide: a small chain of protein building blocks.

It was first found in the thymus, a chest gland that helps the body's immune defences develop.

The lab-made version is called thymalfasin.

FDA explanation of the peptide

An offer is not an answer

In its 2024 review, the FDA found online offers for injections and nasal sprays, including a false claim of FDA approval.

That review found too little evidence to establish benefit for any of the uses it assessed.

This leaves useful questions: what is the product, what supports its use for your concern, and what other care is available?

FDA review of offers and evidence

Choose your next question

Find an answer for your next decision.

The exact name Start with the exact name. US approval Approval has a place attached. Compounding Taking back a request does not let pharmacies make this medicine. Evidence for benefit An immune effect is not a proven benefit. A major trial A hopeful result needs a careful test. Caution notes The product matters as much as the name. Care checks Check the record behind the badge. The assessment A treatment menu is not an assessment. Questions to bring Ask what each test is for. Budget notes Get a written total, not a headline. Red-flag notes A research label does not make it care. Source notebook An entry is not an endorsement.